DHR Q2 FY2026 earnings: EPS beat by 5.4%, revenue beat by 2.6%
DANAHER CORP /DE/ reported Q2 FY2026. EPS came in at $1.94 against a $1.84 consensus, beat by 5.4%. Revenue was $6.3B versus $6.1B expected, beat by 2.6%. Gross margin was 57.6%, down 270 bps from last quarter.
Guidance “The trends we're seeing in the business, together with healthy underlying demand, reinforce our confidence in the high single-digit long-term outlook for Cytiva's bioprocessing franchise.”
Guidance “As end market conditions continue to improve, we expect commercial and go-to-market execution, including autonomous lab-catalyzed demand, to further support growth acceleration across Abcam, IDT, and Aldevron.”
4 more flagged statements from this call are in the Pro read.
Subscribe — $9.99/mo →| Metric | Actual | Consensus | Surprise |
|---|---|---|---|
| EPS | $1.94 | $1.84 | beat by 5.4% |
| Revenue | $6.3B | $6.1B | beat by 2.6% |
| Line | This quarter | QoQ | YoY |
|---|---|---|---|
| Revenue | $6.3B | +5.3% | +5.5% |
| Gross profit | $3.6B | +0.6% | -8.7% |
| Operating income | $1.1B | -16.1% | -5.5% |
| Net income | $870.0M | -15.5% | +56.8% |
| Diluted EPS | $1.23 | -15.2% | +59.7% |
| Gross margin: 57.6%. |
Revenue is up 5.5% from the same quarter last year. Gross margin sits at 57.6%, 900 bps off its 8-quarter high.
This section is part of the Pro report for DHR.
Subscribe — $9.99/mo →The week in semiconductors, in your inbox. Free.
Every Saturday: the tape, the rotation, the prints that mattered, and what the desk is watching next week. No noise.
Get it every Saturday →